NTLA — Intellia Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-05-06.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NTLA
| date | signal | measured base rate |
|---|---|---|
| 2026-08-10 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-16 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-10 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-29 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-05-19 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-14 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-22 | Dulac Edward J III EVP, Chief Financial Officer | Open-market sale | 8.1K | 11.25 | 91.2K |
| 2026-07-02 | Dulac Edward J III EVP, Chief Financial Officer | Open-market sale 10b5-1 plan | 4.7K | 18.00 | 84.2K |
| 2026-07-01 | Dube Michael P VP, Chief Accounting Officer | Open-market sale | 2.6K | 16.78 | 44.3K |
| 2026-06-09 | Cohen Fred E Director | Grant or award | 9.2K | 0.00 | 0 |
| 2026-06-09 | Verwiel Frank Director | Grant or award | 9.2K | 0.00 | 0 |
| 2026-06-09 | GOODMAN JESSE Director | Grant or award | 9.2K | 0.00 | 0 |
| 2026-06-09 | Keresty Georgia Director | Grant or award | 9.2K | 0.00 | 0 |
| 2026-06-09 | Goff Brian Director | Grant or award | 9.2K | 0.00 | 0 |
| 2026-06-09 | CHASE WILLIAM J Director | Grant or award | 9.2K | 0.00 | 0 |
| 2026-06-09 | Bhanji Muna Director | Grant or award | 9.2K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ARK Investment Management LLC | 186.0M | 14.5M |
| BlackRock, Inc. | 155.8M | 12.2M |
| STATE STREET CORP | 88.7M | 6.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 79.8M | 6.2M |
| D. E. Shaw & Co., Inc. | 73.4M | 5.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 65.2M | 5.1M |
| TWO SIGMA INVESTMENTS, LP | 60.3M | 4.7M |
| REGENERON PHARMACEUTICALS, INC. | 47.5M | 3.7M |
| GEODE CAPITAL MANAGEMENT, LLC | 36.6M | 2.9M |
| UBS Group AG | 34.5M | 2.7M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about NTLA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →